Elusive proof-of-principle

Gene therapy companies reported a mixed bag of results at last week's American Society of Clinical Oncology meeting in Denver, but none of it was sufficiently robust to suggest yet that proof of principle for the technology can be established under the FDA's more aggressive approach to cancer treatments.

On the more optimistic side, Introgen Therapeutics Inc. (Austin, Texas) and partner RPR Gencell (Vitry, France) plan to move into Phase II trials of Introgen's p53 tumor suppressor gene in advanced head and neck cancer this year, based on their